These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3572025)

  • 1. Inhibition of transformation by levodopa-carbidopa in lymphocytes derived from patients with melanoma.
    Wick MM
    J Invest Dermatol; 1987 May; 88(5):535-7. PubMed ID: 3572025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Senek M; Nielsen EI; Nyholm D
    Mov Disord; 2017 Feb; 32(2):283-286. PubMed ID: 27987231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The chemotherapy of malignant melanoma.
    Wick MM
    J Invest Dermatol; 1983 Jun; 80 Suppl():61s-62s. PubMed ID: 6854056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa with carbidopa diminishes glycogen concentration, glycogen synthase activity, and insulin-stimulated glucose transport in rat skeletal muscle.
    Smith JL; Ju JS; Saha BM; Racette BA; Fisher JS
    J Appl Physiol (1985); 2004 Dec; 97(6):2339-46. PubMed ID: 15258132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma.
    Wick MM
    Cancer Res; 1980 May; 40(5):1414-8. PubMed ID: 6768447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with parkinson's disease.
    Leibowitz M; Lieberman A
    Neurology; 1975 Oct; 25(10):917-21. PubMed ID: 52131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
    Catalán MJ; Escribano PM; Alonso-Frech F
    Mov Disord; 2017 Apr; 32(4):624-625. PubMed ID: 28116835
    [No Abstract]   [Full Text] [Related]  

  • 11. Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells.
    Wick MM
    J Invest Dermatol; 1989 May; 92(5 Suppl):329S-331S. PubMed ID: 2715667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Ricciardi L; Bove F; Espay KJ; Lena F; Modugno N; Poon YY; Krikorian R; Espay AJ; Fasano A
    Mov Disord; 2016 Apr; 31(4):597-8. PubMed ID: 26946221
    [No Abstract]   [Full Text] [Related]  

  • 13. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
    Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
    Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
    Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of levodopa/carbidopa on stress response in zebrafish.
    Idalencio R; Lopes TM; Soares SM; Pompermaier A; de Alcantara Barcellos HH; Kalichak F; Fagundes M; de Oliveira CM; Barcellos LJG
    J Comp Physiol A Neuroethol Sens Neural Behav Physiol; 2021 May; 207(3):393-399. PubMed ID: 33772638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of levodopa with carbidopa (Sinemet R) on the metabolic response to semistarvation.
    Jung RT; Liddell F; Shetty PS; James WP
    Int J Obes; 1980; 4(3):221-6. PubMed ID: 7419340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice.
    Törnwall M; Tuomainen P; Männistö PT
    Arch Int Pharmacodyn Ther; 1992; 320():5-20. PubMed ID: 1300941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
    Yahr MD; Clough CG; Bergmann KJ
    Lancet; 1982 Sep; 2(8300):709-10. PubMed ID: 6126641
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.